Skip to main content
Top
Published in: Clinical Rheumatology 5/2004

01-10-2004 | Original Article

Clinical evaluation of insulin resistance and β-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus

Authors: Tim K. Tso, Hui-Yu Huang, Chen-Kang Chang, Ying-Ju Liao, Wen-Nan Huang

Published in: Clinical Rheumatology | Issue 5/2004

Login to get access

Abstract

The aim of this preliminary study was to evaluate insulin resistance and secretion using homeostasis model assessment (HOMA) in patients with systemic lupus erythematosus (SLE). The fasting glucose and insulin concentrations, HOMA insulin resistance (IR), HOMA β-cell, antidouble-stranded DNA antibodies (anti-dsDNA), C3, C4, and SLE disease activity index (SLEDAI) were determined in a total of 58 female SLE patients. All patients were classified into subgroups according to the presence of anticardiolipin antibodies (aCL+ vs. aCL-) and SLEDAI scores (SLEDAI <3 vs. SLEDAI >3). Results showed that SLE patients with and without aCL had significantly higher fasting insulin levels, HOMA IR, and HOMA β-cells than controls. Similar results were also found in SLE patients with different disease activities. Pearson’s correlation analysis showed that there was a highly significant correlation of HOMA IR with fasting insulin concentration in the SLE patients and SLE subgroups overall. However, HOMA β-cells were positively correlated with HOMA IR and fasting insulin level, but negatively correlated with fasting glucose concentration in SLE patients overall. In conclusion, SLE patients, regardless of the presence of aCL and different disease activities, had a higher risk of insulin resistance and abnormal insulin secretion than age-matched healthy controls, based on fasting insulin concentration, HOMA IR, and HOMA β-cells.
Literature
1.
go back to reference Moller DE, Flier JS (1991) Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 325:938–948PubMed Moller DE, Flier JS (1991) Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 325:938–948PubMed
2.
go back to reference Flier JS, Kahn CR, Roth J (1979) Receptors, antireceptor antibodies and mechanisms of insulin resistance. N Engl J Med 300:413–419PubMed Flier JS, Kahn CR, Roth J (1979) Receptors, antireceptor antibodies and mechanisms of insulin resistance. N Engl J Med 300:413–419PubMed
3.
go back to reference Accili D, Barbetti F, Cama A et al. (1992) Mutations in the insulin receptor gene in patients with genetic syndromes of insulin resistance and acanthosis nigricans. J Invest Dermatol 98:77S–81SPubMed Accili D, Barbetti F, Cama A et al. (1992) Mutations in the insulin receptor gene in patients with genetic syndromes of insulin resistance and acanthosis nigricans. J Invest Dermatol 98:77S–81SPubMed
4.
go back to reference Kahn CR, Flier JS, Bar RS et al. (1976) The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. N Engl J Med 294:739–745PubMed Kahn CR, Flier JS, Bar RS et al. (1976) The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. N Engl J Med 294:739–745PubMed
5.
go back to reference Moller DE, Flier JS (1988) Detection of an alteration in the insulin-receptor gene in a patients with insulin resistance, acanthosis nigricans, and polycystic ovary syndrome (type A insulin resistance). N Engl J Med 319:1526–1529PubMed Moller DE, Flier JS (1988) Detection of an alteration in the insulin-receptor gene in a patients with insulin resistance, acanthosis nigricans, and polycystic ovary syndrome (type A insulin resistance). N Engl J Med 319:1526–1529PubMed
6.
go back to reference Steinberg AD, Klinman DM (1988) Pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 14:25–41PubMed Steinberg AD, Klinman DM (1988) Pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 14:25–41PubMed
7.
go back to reference Magsino CH, Spencer J (1999) Insulin receptor antibodies and insulin resistance. South Med J 92:717–719PubMed Magsino CH, Spencer J (1999) Insulin receptor antibodies and insulin resistance. South Med J 92:717–719PubMed
8.
go back to reference Eriksson JW, Bremell T, Eliasson B, Fowelin J, Fredriksson L, Yu ZW (1998) Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Case report. Diabetes Care 21:1217–1220PubMed Eriksson JW, Bremell T, Eliasson B, Fowelin J, Fredriksson L, Yu ZW (1998) Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance. Case report. Diabetes Care 21:1217–1220PubMed
9.
go back to reference Yamasaki H, Yamaguchi Y, Fujita N et al. (2000) Anti-insulin receptor autoantibodies in a patient with type B insulin resistance and fasting hypoglycemia. Acta Diabetol 37:189–196CrossRefPubMed Yamasaki H, Yamaguchi Y, Fujita N et al. (2000) Anti-insulin receptor autoantibodies in a patient with type B insulin resistance and fasting hypoglycemia. Acta Diabetol 37:189–196CrossRefPubMed
10.
go back to reference Baird JS, Johnson JL, Elliott-Mills D, Opas LM (1997) Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody. Lupus 6:275–278PubMed Baird JS, Johnson JL, Elliott-Mills D, Opas LM (1997) Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody. Lupus 6:275–278PubMed
11.
go back to reference Gehi A, Webb A, Nolte M, Davis J (2003) Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum 48:1067–1070 Gehi A, Webb A, Nolte M, Davis J (2003) Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum 48:1067–1070
12.
go back to reference Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P (2002) Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 81:87–100 Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI, Gorden P (2002) Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 81:87–100
13.
go back to reference Tardella L, Rossetti L, De Pirro R et al. (1983) Circulating anti-insulin receptor antibodies in a patient suffering from lupus nephritis and hypoinsulinemic hypoglycemia. J Clin Lab Immunol 12:159–165PubMed Tardella L, Rossetti L, De Pirro R et al. (1983) Circulating anti-insulin receptor antibodies in a patient suffering from lupus nephritis and hypoinsulinemic hypoglycemia. J Clin Lab Immunol 12:159–165PubMed
14.
go back to reference Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI (2002) Insulin resistance and risk for stroke. Neurology 59:809-815PubMed Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI (2002) Insulin resistance and risk for stroke. Neurology 59:809-815PubMed
15.
go back to reference Haffner SM, Miettinen H, Stern MP (1997) The homeostasis model in the San Antonio Heart Study. Diabetes Care 20:1087–1092 Haffner SM, Miettinen H, Stern MP (1997) The homeostasis model in the San Antonio Heart Study. Diabetes Care 20:1087–1092
16.
go back to reference Tan EM, Cohen AS, Fries JF et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed Tan EM, Cohen AS, Fries JF et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed
17.
go back to reference Chang DM, Lan JL, Lin HY, Luo SF (2002) Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus. Arthritis Rheum 46:2924–2927CrossRefPubMed Chang DM, Lan JL, Lin HY, Luo SF (2002) Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus. Arthritis Rheum 46:2924–2927CrossRefPubMed
18.
go back to reference Bombardier C, Gladman DD, Urowitz MB et al. (1992) Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630–640PubMed Bombardier C, Gladman DD, Urowitz MB et al. (1992) Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630–640PubMed
19.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419PubMed
20.
go back to reference Anderson RL, Hamman RF, Savage PJ et al. (1995) Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests: the Insulin Resistance Atherosclerosis Study. Am J Epidemiol 142:724–732PubMed Anderson RL, Hamman RF, Savage PJ et al. (1995) Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests: the Insulin Resistance Atherosclerosis Study. Am J Epidemiol 142:724–732PubMed
21.
go back to reference Hollenbeck CB, Chen N, Chen YDI, Reaven GM (1984) Relationship between the plasma insulin response to oral glucose and insulin stimulated glucose utilization in normal subjects. Diabetes 33:460–463PubMed Hollenbeck CB, Chen N, Chen YDI, Reaven GM (1984) Relationship between the plasma insulin response to oral glucose and insulin stimulated glucose utilization in normal subjects. Diabetes 33:460–463PubMed
22.
go back to reference Saad MF, Anderson RL, Laws A et al. (1994) A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 43:1114–1121 Saad MF, Anderson RL, Laws A et al. (1994) A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Diabetes 43:1114–1121
23.
go back to reference Laakso M (1993) How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959–965PubMed Laakso M (1993) How good a marker is insulin level for insulin resistance? Am J Epidemiol 137:959–965PubMed
24.
go back to reference Rodriguez O, Collier E, Arakaki R, Gorden P (1992) Characterization of purified autoantibodies to the insulin receptor from six patients with type B insulin resistance. Metabolism 41:325–331CrossRefPubMed Rodriguez O, Collier E, Arakaki R, Gorden P (1992) Characterization of purified autoantibodies to the insulin receptor from six patients with type B insulin resistance. Metabolism 41:325–331CrossRefPubMed
25.
go back to reference Flier JS, Kahn CR, Roth J, Bar RS (1975) Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 190:63–65PubMed Flier JS, Kahn CR, Roth J, Bar RS (1975) Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 190:63–65PubMed
26.
go back to reference Flier JS, Kahn CR, Jarrett DB, Roth J (1976) Characterization of antibodies to the insulin receptor: a cause of insulin-resistant diabetes in man. J Clin Invest 58:1442–1449PubMed Flier JS, Kahn CR, Jarrett DB, Roth J (1976) Characterization of antibodies to the insulin receptor: a cause of insulin-resistant diabetes in man. J Clin Invest 58:1442–1449PubMed
Metadata
Title
Clinical evaluation of insulin resistance and β-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus
Authors
Tim K. Tso
Hui-Yu Huang
Chen-Kang Chang
Ying-Ju Liao
Wen-Nan Huang
Publication date
01-10-2004
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2004
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0908-5

Other articles of this Issue 5/2004

Clinical Rheumatology 5/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine